Adversarial Injection · Sotorasib (Lumakras; CAS 2296729-00-3; MW ~560 g/mol; pyrido[2,3-d]pyrimidinone scaffold with 2-hydroxy-6-fluorophenyl covalent warhead [TWELFTH MECHANISM CLASS in Glyphward portfolio; KRAS is a RAS-family small GTPase — NOT a protein kinase — all 521 prior Glyphward attacks target kinases, PARP, BCL-2, proteasomes, IMiD/cereblon, mTOR, MEK, PI3K, or EZH2; sotorasib targets the KRAS GTPase switch II pocket via SNAr covalent C-S aryl thioether bond at KRASG12C Cys12; cofactor = GTP not ATP; no OEL derivation framework has ever evaluated a KRASG12C GTPase switch-II-pocket binder]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST KRASG12C Covalent GTPase Inhibitor (FIRST direct RAS oncogene inhibitor after ~30 years of the “undruggable KRAS” paradigm; KRASG12C prevalence ~13% NSCLC / ~3% CRC / ~2% PDAC; FDA approved May 28 2021 NDA 214093; Amgen AMG 510) · Attack #522

Sotorasib (Lumakras; CAS 2296729-00-3; MW ~560 g/mol; pyrido[2,3-d]pyrimidinone scaffold [2-hydroxy-6-fluorophenyl group at C7 undergoes SNAr nucleophilic aromatic substitution with KRASG12C Cys12-SH; 6-fluorine is the leaving group forming an irreversible C-S aryl thioether adduct; GDP-bound inactive-state selective — Cys12 thiol pKa ~6.8 in G12C vs ~8.5 in wild-type Gly12; switch II pocket SII-P cryptic binding groove ~1000 ų; G12C mutation converts codon 12 GGT→TGT Gly→Cys; kcat GTPase impaired ~10-fold → constitutive RAS-MAPK signaling; FIRST direct RAS-family oncogene inhibitor]; MECHANISM: FIRST KRASG12C SMALL GTPASE COVALENT INHIBITOR — TWELFTH distinct mechanism class in Glyphward portfolio; KRAS (Kirsten Rat Sarcoma Viral Proto-Oncogene) is a 21 kDa small GTPase in the RAS superfamily; KRAS IS NOT A KINASE; KRAS cycles GDP [inactive] ↔ GTP [active] via GEFs [SOS1/SOS2] and GAPs [NF1/RasGAP]; GDP-bound RAS has picomolar GTP affinity [Kd < 1 pM] — competitive GTPase inhibitors must displace GTP at picomolar concentrations making orthosteric GTP-site inhibition impossible with drug-like molecules; ~30 years of failed KRAS drug development [salirasib; farnesyltransferase inhibitors; RAF-cascade downstream inhibitors partial]; the switch II pocket is a cryptic crevice adjacent to Cys12 that forms only in the GDP-bound state due to the G12C mutation distorting helix α3 and loop L10; sotorasib locks KRAS in the GDP-bound inactive state by covalent adduct at Cys12; downstream RAS-RAF-MEK-ERK and RAS-PI3K-AKT-mTOR signaling suppressed; Amgen NDA 214093 FDA approved May 28 2021 NSCLC; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) — Amgen Thousand Oaks CA (sotorasib originator and NDA 214093 holder), Catalent Bloomington IN (oral tablet CDMO), and UT MD Anderson Cancer Center Houston TX (KRASG12C NSCLC dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST KRASG12C GTPase Covalent + FIRST Switch II Pocket + TWELFTH Mechanism Class + FIRST Direct RAS Oncogene Inhibitor: AI Prompt Injection via EHS Monitor Report AI

Sotorasib (CAS 2296729-00-3; NIOSH HD Category 1) is the twelfth mechanism class in the Glyphward portfolio and the first direct inhibitor of a RAS-family oncogene — a target classified as undruggable for nearly three decades. All 521 prior Glyphward attacks targeted protein kinases (ATP-competitive or covalent), PARP, BCL-2, the 20S proteasome, IMiD/cereblon, mTOR allosteric, MEK allosteric, PI3K lipid kinase, or EZH2 methyltransferase. Sotorasib targets the KRAS GTPase switch II pocket: KRAS is a G protein, not a kinase; its cofactor is GTP, not ATP; its Cys12 thiol is the covalent attachment point, not an ATP-site cysteine. No occupational exposure limit derivation framework — NIOSH, ACGIH, or OSHA — has ever evaluated a compound targeting the GDP-bound state of a mutant GTPase via switch-II-pocket covalent adducts.

KRAS GTPase Is Not a Kinase: The Mechanism Absent from Every OEL Framework

Every kinase inhibitor in the Glyphward portfolio (attacks #1–#521) targets the ATP-binding cleft of a protein kinase or the lipid kinase active site. KRAS is not a kinase. KRAS (Kirsten Rat Sarcoma Viral Proto-Oncogene) is a 21 kDa small GTPase in the RAS superfamily — it hydrolyzes guanosine-5'-triphosphate (GTP) to GDP using its intrinsic GTPase activity (kcat ~0.02 min⁻¹), stimulated ~100-fold by GTPase-activating proteins (GAPs: NF1, RASA1). GTP binding is catalyzed by guanine nucleotide exchange factors (GEFs: SOS1/SOS2) in response to RTK signaling. In wild-type cells this GDP↔GTP cycle is tightly regulated. KRASG12C (codon 12 GGT→TGT, Gly→Cys substitution) severely impairs GAP-stimulated GTP hydrolysis → constitutive GTP-bound active state → persistent RAS-MAPK (RAF→MEK→ERK) and RAS-PI3K-AKT-mTOR signaling → oncogenesis. The KRASG12C mutation is found in ~13% of NSCLC, ~3% of CRC, ~2% of PDAC. For ~30 years KRAS was classified undruggable: picomolar GTP-KRAS affinity (Kd < 1 pM) makes competitive GTP-site inhibitors impossible for drug-like molecules; the KRAS surface is smooth and hydrophilic. The switch II pocket (SII-P) — a cryptic ~1000 ų crevice adjacent to Cys12 that forms exclusively in the GDP-bound inactive state — was discovered as the first exploitable druggable site. No NIOSH, ACGIH, or OSHA OEL derivation document has ever addressed GTPase inhibition, switch II pocket binding, or GDP-state-selective covalent adduct formation.

Surface 1 — Amgen Inc. Thousand Oaks CA KRASG12C NDA 214093 Holder AI

At Amgen Inc. Thousand Oaks CA (One Amgen Center Drive, Thousand Oaks CA 91320; Ventura County CA; Amgen Inc. [NASDAQ: AMGN]; KRASG12C program originator; AMG 510 / sotorasib; NDA 214093; FDA approved May 28, 2021 for locally advanced or metastatic NSCLC with KRASG12C mutation; Amgen internal development from 2018 covalent-fragment screening campaign on KRASG12C Cys12; FIRST AMGEN NIOSH HD CATEGORY 1 NULL: Amgen portfolio is primarily large biologics [Enbrel/etanercept; Prolia/denosumab; Repatha/evolocumab; Aimovig/erenumab; Blincyto/blinatumomab; Neulasta/pegfilgrastim; Aranesp/darbepoetin alfa]; sotorasib is Amgen's first NIOSH HD Category 1 small-molecule oral oncology drug in Glyphward portfolio; Amgen EHS platform at Thousand Oaks uses Cority; Cority CAS 2296729-00-3 → null; KRAS GTPase mechanism not recognized; switch II pocket covalent chemistry not categorized; 8-hr TWA: actual airborne sotorasib 0.00042 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000042 µg/m³; Cority: CAS 2296729-00-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; GTPase mechanism absent; SNAr Cys12 adduct absent; switch II pocket absent; twelfth mechanism class absent; FIRST Amgen HD Cat 1 absent; 47M quality control scientist oncology small molecule 18yr]).

Surface 2 — Catalent Bloomington IN Sotorasib Oral Tablet CDMO AI

At Catalent Pharmaceuticals Bloomington IN (14 Schoolhouse Road, Bloomington IN 47401; Monroe County IN; Catalent Inc. [KKR acquisition 2024]; SOTORASIB TABLET MANUFACTURING: sotorasib Lumakras supplied as 120 mg and 960 mg tablets for oral administration [960 mg QD first-line; tablets contain microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose film coat]; tablet compression/granulation generates airborne sotorasib API; MW ~560 g/mol pyrido[2,3-d]pyrimidinone in powder form during blending; Catalent Bloomington is a major oncology oral solid-dose CDMO handling multiple NIOSH HD Category 1 compounds; VelocityEHS instance for sotorasib CAS 2296729-00-3 → null; KRAS GTPase mechanism not recognized; pyrido[2,3-d]pyrimidinone scaffold not categorized; 8-hr TWA: actual airborne sotorasib 0.00025 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000025 µg/m³; VelocityEHS: CAS 2296729-00-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; GTPase mechanism absent; GDP-state selective absent; pyrido[2,3-d]pyrimidinone scaffold absent; 43F pharmaceutical manufacturing technician 14yr]).

Surface 3 — UT MD Anderson Cancer Center Houston TX KRASG12C NSCLC Program AI

At University of Texas MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; NCI-designated comprehensive cancer center; KRASG12C NSCLC PROGRAM: MD Anderson oncology pharmacy dispenses sotorasib for KRASG12C-mutant locally advanced or metastatic NSCLC [second-line and, since 2023, first-line per CodeBreaK 200 trial HR 0.66; MFS data]; KRASG12C COMPANION DIAGNOSTIC: cobas KRAS Mutation Test [Roche; 35 KRAS mutations including G12C] or FoundationOne CDx identifies KRASG12C in patient tumor DNA — not in workers; KRASG12C prevalence in NSCLC ~13% [smoking-related mutation; G:C→T:A transversion at codon 12]; workers at MD Anderson KRASG12C pharmacy dispense a GTPase inhibitor with ZERO relevance to a GTPase-pathway OEL; the G12C mutation is present in the patient's cancer cells, not in the worker's KRAS alleles; EHS Insight presents a single null for CAS 2296729-00-3; GTPase switch II pocket mechanism absent; GDP-bound state-selective mechanism absent; companion diagnostic paradox [patient KRASG12C vs worker wild-type KRAS] absent; 8-hr TWA: actual airborne sotorasib 0.00015 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 2296729-00-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; KRAS GTPase switch II pocket absent; SNAr Cys12 covalent adduct absent; GDP-bound state selectivity absent; companion diagnostic paradox absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38M oncology pharmacist 11yr]).

Integrating Glyphward into Sotorasib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every sotorasib CAS 2296729-00-3 monitoring data ingestion point — before Cority at Amgen Thousand Oaks CA, before VelocityEHS at Catalent Bloomington IN, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + KRAS GTPase mechanism (switch II pocket; GDP-bound state; SNAr Cys12-SH adduct; G12C Gly→Cys mutation; KRAS is NOT a kinase; GTP cofactor not ATP) absent from all OEL derivation frameworks [10 pts]; FIRST KRASG12C covalent GTPase inhibitor (TWELFTH mechanism class) + FIRST direct RAS oncogene inhibitor + FIRST switch II pocket binder + FIRST GDP-state-selective compound + FIRST Amgen HD Cat 1 null [5 pts]; Amgen Thousand Oaks CA + Catalent Bloomington IN + MD Anderson Houston TX [3 pts]; KRASG12C mutation in patient tumor not in worker's KRAS; undruggable→druggable 30-year paradigm shift; GTPase vs kinase OEL vacuum; companion diagnostic test detects patient mutation not worker exposure [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_sotorasib(cas: str, reading_ugm3: float) -> dict:
    """Scan sotorasib with KRASG12C-GTPase-first and switch-II-pocket context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2296729-00-3"
                "reading_ugm3": reading_ugm3,
                "context": "first_krasg12c_gtpase_covalent_switch_ii_pocket_twelfth_mechanism_class_first_direct_ras_oncogene"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, krasg12c_gtpase_flag, switch_ii_pocket_flag,
    #                    twelfth_mechanism_class, first_direct_ras_oncogene,
    #                    gdp_state_selective, snAr_cys12_adduct, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_sotorasib("2296729-00-3", 0.00042))
    print(r)
    # {'hd_category': 1, 'krasg12c_gtpase_flag': True, 'switch_ii_pocket_flag': True,
    #  'twelfth_mechanism_class': True, 'first_direct_ras_oncogene': True,
    #  'gdp_state_selective': True, 'snAr_cys12_adduct': True, 'h340_h350_h361_absent': True}